

Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.3 30.11.2023 10844547-00005 Date of first issue: 06.09.2022

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Cefuroxime Formulation

Other means of identification : Spectrazol Milking Cow (A005270)

Coopers Cepravin LC Lactating Cow Intramammary Antibiotic

(47941)

Manufacturer or supplier's details

Company : MSD

Address : 50 Tuas West Drive

Singapore - Singapore 638408

Telephone : +1-908-740-4000

Emergency telephone number : 65 6697 2111 (24/7/365)

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

GHS Classification

Respiratory sensitisation : Category 1

GHS label elements

Hazard pictograms :

Signal word : Danger

Hazard statements : H334 May cause allergy or asthma symptoms or breathing

difficulties if inhaled.

Precautionary statements : Prevention:

P261 Avoid breathing mist or vapours. P284 Wear respiratory protection.

Response:

P304 + P340 IF INHALED: Remove person to fresh air and



Cefuroxime Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.3
 30.11.2023
 10844547-00005
 Date of first issue: 06.09.2022

keep comfortable for breathing.

P342 + P311 If experiencing respiratory symptoms: Call a

POISON CENTER/ doctor.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

Additional Labelling

The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 8.33 %

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cefuroxime	55268-75-2	>= 1 -< 10

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Get medical attention if symptoms occur. Flush eyes with water as a precaution.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur.

Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and delayed

May cause allergy or asthma symptoms or breathing difficul-

ties if inhaled.

Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reac-

tive airways dysfunction syndrome).

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.



Cefuroxime Formulation

Revision Date: SDS Number: Date of last issue: 30.09.2023 Version 2.3 30.11.2023 10844547-00005 Date of first issue: 06.09.2022

5. FIREFIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Sulphur oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

Evacuate area.

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec: :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

7. HANDLING AND STORAGE



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.3 30.11.2023 10844547-00005 Date of first issue: 06.09.2022

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation. Advice on safe handling : Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Already sensitised individuals, and those susceptible

to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respira-

tory irritants or sensitisers.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labelled containers.

Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis	
Cefuroxime	55268-75-2	TWA	100 μg/m3 (OEB 2)	Internal	
	Further information: RSEN				

Engineering measures : Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type

Hand protection

_.

Particulates type

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.3 30.11.2023 10844547-00005 Date of first issue: 06.09.2022

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Hygiene measures

Work uniform or laboratory coat.

If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the work-

ing place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid

Colour : white

off-white

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.3 30.11.2023 10844547-00005 Date of first issue: 06.09.2022

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : Not applicable

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.

Possibility of hazardous reac- :

tions

Can react with strong oxidizing agents.

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents

Hazardous decomposition

products

No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of : exposure

Inhalation
Skin contact
Ingestion

Eye contact

Acute toxicity

Not classified based on available information.

Components:

Cefuroxime:

Acute oral toxicity : LD50 (Rat): > 10,000 mg/kg



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.3 30.11.2023 10844547-00005 Date of first issue: 06.09.2022

LD50 (Mouse): > 10,000 mg/kg

Acute toxicity (other routes of :

administration)

LD50 (Rat): > 4,000 mg/kg Application Route: Intravenous

LD50 (Mouse): > 10,000 mg/kg Application Route: Intravenous

LD50 (Rabbit): > 1,500 mg/kg Application Route: Intravenous

LD50 (Dog): > 1,500 mg/kg Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Cefuroxime:

Result : Sensitiser

Germ cell mutagenicity

Not classified based on available information.

Components:

Cefuroxime:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration

Result: positive

Test Type: In vitro mammalian cell gene mutation test

Test system: mouse lymphoma cells

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Result: negative



Cefuroxime Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 2.3
 30.11.2023
 10844547-00005
 Date of first issue: 06.09.2022

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

Components:

Cefuroxime:

Effects on fertility : Test Type: Fertility

Species: Mouse

Application Route: Oral

Fertility: NOAEL: 6,400 mg/kg body weight

Symptoms: No adverse effects

Test Type: Fertility Species: Rabbit

Application Route: Oral

Fertility: NOAEL: 400 mg/kg body weight

Symptoms: No adverse effects

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

Cefuroxime:

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Cefuroxime:

Species : Rat

NOAEL : 900 mg/kg Application Route : Subcutaneous

Exposure time : 3 M

Symptoms : No adverse effects

Species : Dog NOAEL : 400 mg/kg LOAEL : 1,600 mg/kg

Application Route : Oral Exposure time : 27 W Target Organs : Blood

Symptoms : Gastrointestinal disturbance



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.3 30.11.2023 10844547-00005 Date of first issue: 06.09.2022

Species : Monkey
NOAEL : 450 mg/kg
Application Route : Subcutaneous

Exposure time : 1 M

Target Organs : Blood, Urinary tract

Remarks : May cause damage to organs.

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Cefuroxime:

General Information : Repeated contact may cause allergic reactions in very sus-

ceptible persons.

Inhalation : Symptoms: Nausea, Vomiting, Abdominal pain, vaginitis,

Headache, Dizziness, dry mouth, Fatigue, constipation, colitis

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cefuroxime:

Ecotoxicology Assessment

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

Persistence and degradability

No data available

Bioaccumulative potential

Components:

Cefuroxime:

Partition coefficient: n- : log Pow: -0.429

octanol/water

Mobility in soil

No data available

Other adverse effects

No data available



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.3 30.11.2023 10844547-00005 Date of first issue: 06.09.2022

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo : Not applicable

aircraft)

Packing instruction (passen-

ger aircraft)

Not applicable

IMDG-Code

UN number Not applicable Proper shipping name Not applicable Class Not applicable Subsidiary risk Not applicable Not applicable Packing group Labels Not applicable **EmS Code** Not applicable Not applicable Marine pollutant

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

Not applicable



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.3 30.11.2023 10844547-00005 Date of first issue: 06.09.2022

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.

Environmental Protection and Management Act and

Environmental Protection and Management (Hazard-

ous Substances) Regulations

Fire Safety (Petroleum and Flammable Materials)

Regulations

Not applicable

: Not applicable

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 30.11.2023

Further information

Sources of key data used to compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Or-



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 2.3 30.11.2023 10844547-00005 Date of first issue: 06.09.2022

ganisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose): MARPOL - International Convention for the Prevention of Pollution from Ships: n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration: NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN